# EDGAR Filing Document

**Accession Number:** 0000799698
**File Stem:** 0001641172-25-016785
**Filing Date:** 2025-6
**Character Count:** 4479
**Document Hash:** 2119d16ea9158dfb3551b547872736f7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-016785.hdr.sgml**: 20250627

**ACCESSION NUMBER**: 0001641172-25-016785

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250611

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20250627

**DATE AS OF CHANGE**: 20250627

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LadRx Corp
- **CENTRAL INDEX KEY:** 0000799698
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 581642750
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-15327
- **FILM NUMBER:** 251082063

**BUSINESS ADDRESS:**
- **STREET 1:** 11726 SAN VICENTE BOULEVARD
- **STREET 2:** SUITE 650
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90049
- **BUSINESS PHONE:** 310-826-5648

**MAIL ADDRESS:**
- **STREET 1:** 11726 SAN VICENTE BOULEVARD
- **STREET 2:** SUITE 650
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90049

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTRX CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 11, 2025**

**LADRX CORPORATION**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-15327** | **58-1642740** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

**11726 San Vicente Boulevard, Suite 650**

**Los Angeles, California 90049**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(310) 826-5648**

Former name or former address, if changed since last report: **None**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(g) of the Act:**

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock, par value $0.001 per share Series B Junior Participating Preferred Stock Purchase Rights** | **LADX** | **OTC Markets** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

On December 11, 2024, LadRx Corporation (the "***Company***") announced its intent to approach the Food and Drug Administration (the "***FDA***") with a proposal to use the existing clinical data and supplemental non-clinical data to seek marketing approval for aldoxorubicin under section 505(b)(2). As a result of conducting additional research and records reviews, management has formed the opinion that while obtaining a marketing approval under section 505(b)(2) is possible, the Company does not have the resources available to conduct the likely necessary activities to gain approval.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | **LADRX CORPORATION** |
| Date: June 27, 2025 | */s/ John Y. Caloz* |
|  | John Y. Caloz |
|  | Chief Financial Officer |

---